Drug Approval | March 01, 2024
Biocon Biologics secures US market entry date for Bmab 1200
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Patients visiting OPD sections of hospitals use their Ayushman Bharat Health Account (ABHA) to get instant tokens to save time spent in registration queues
Project achieves 30% reduction in hospital acquired infections and 24% reduction in the incidence of multi-drug resistant organisms
The company's SaaS solutions are tailored to enhance accessibility, efficiency, and patient-centricity in healthcare operations
The 200 bedded hospital owned & operated by Alexis
The company also plans to boost its India presence by adding 1,500 beds in the next 2-3 years
10+ emerging markets, Japan & ANZ transition in final phase
Leading USA based genetic testing brand officially enters the Indian market
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Both the India and GCC entities will be operated by separate dedicated management teams
Subscribe To Our Newsletter & Stay Updated
